RFK Jr.'s HHS Nomination Shakes Markets and Sparks Controversy
TL;DR
Vaccine and pharmaceutical stocks fell sharply after Donald Trump nominated vaccine skeptic Robert F. Kennedy Jr. as the head of the US Department of Health and Human Services. Kennedy's controversial views on vaccines and the FDA have raised concerns about potential policy changes, impacting companies like Moderna, Pfizer, GSK, and Sanofi. The nomination is expected to face a challenging Senate confirmation process. Despite the market reaction, some industry insiders believe Kennedy's ideas are unlikely to become policy.
Topics:nationbusiness#business#fda#pharmaceuticalindustry#robertkennedyjr#trumpadministration#vaccinestocks
- Vaccine stocks hit by Robert Kennedy Jr nomination Financial Times
- Trump’s latest controversial Cabinet pick could have a huge impact on Americans’ health and lives CNN
- 'Nuts on a lot of fronts': New York Post condemns Kennedy pick to lead HHS POLITICO
- Late Night Feels Queasy About America’s Next Health Czar, R.F.K. Jr. The New York Times
- Stock Market Today: Indexes Drop; Dollar Weakens — Live Updates The Wall Street Journal
Want the full story? Read the original reporting
Read on Financial Times